Vyleesi (Bremelanotide) Cost in Alabama: Prices, Insurance, and Savings in 2026

What Brand-Name Vyleesi Costs at Alabama Pharmacies

The manufacturer list price for Vyleesi (bremelanotide 1.75 mg prefilled autoinjector) sits at approximately $1,200 per month across Alabama retail pharmacies in 2026. That figure has remained stable since Palatin Technologies set pricing shortly after FDA approval in June 2019. Per the prescribing label, each dose is a single 1.75 mg subcutaneous injection taken as needed, at least 45 minutes before anticipated sexual activity, with a cap of one dose per 24 hours and no more than eight doses in a calendar month.

Actual out-of-pocket expense depends on how many autoinjectors a patient uses. A woman who uses Vyleesi twice per month pays far less per cycle than someone using it six or seven times. Even so, the per-unit cost is high enough that most Alabama patients explore alternatives. The average wholesale price (AWP) tracks closely with the list price because there is no generic bremelanotide autoinjector on the U.S. market. Retail pharmacy pricing in Birmingham, Huntsville, Mobile, and Montgomery clusters tightly around that $1,200 figure, with negligible variation between chains.

The RECONNECT phase 3 trials (N=1,247 combined) demonstrated that bremelanotide 1.75 mg produced a statistically significant increase in desire scores on the Female Sexual Function Index (FSFI) compared with placebo, supporting the clinical rationale behind the drug. Patients in the active arm reported a mean increase of 0.7 points on the FSFI desire domain versus 0.4 for placebo (P<0.001) [1]. That proven efficacy makes the cost question practical, not academic: women who respond to the drug want sustained access.

Does Alabama Medicaid Cover Vyleesi?

Alabama Medicaid does not cover Vyleesi. The drug is absent from the Alabama Medicaid preferred drug list, and no exception pathway for HSDD medications has been published as of May 2026. This is consistent with most state Medicaid programs nationally. The Centers for Medicare & Medicaid Services gives states broad latitude to exclude drugs for sexual dysfunction from formularies, and Alabama has exercised that discretion.

Patients enrolled in Alabama Medicaid who want bremelanotide therapy have two options. They can pay cash at a retail pharmacy (roughly $1,200/month for brand) or obtain a compounded version through a 503A pharmacy (discussed below). There is no prior-authorization workaround because the drug class itself is excluded, not just the brand.

For dual-eligible patients (those with both Medicare and Medicaid), Medicare Part D plans also generally exclude Vyleesi. The Medicare Part D formulary guidance classifies drugs for sexual dysfunction as a permissible exclusion category, and most plan sponsors use that exclusion.

Which Private Insurance Plans Cover Vyleesi in Alabama?

Coverage is inconsistent. Blue Cross Blue Shield of Alabama, the state's dominant commercial insurer, lists Vyleesi on specialty tier with prior authorization required. Approval criteria typically include a documented HSDD diagnosis, confirmation that the patient is premenopausal, evidence that non-pharmacologic interventions were attempted, and sometimes a trial of flibanserin (Addyi) first.

UnitedHealthcare plans sold on the Alabama exchange and through employer groups have varied. Some 2026 formularies include Vyleesi on a non-preferred specialty tier; others exclude it. Aetna and Cigna plans available in Alabama similarly require prior authorization and may apply step therapy requiring flibanserin first.

Even when a plan covers Vyleesi, the specialty-tier copay can reach $200 to $400 per month before any manufacturer offset. The practical reality for many Alabama women: insurance "coverage" still leaves a significant bill. A 2023 analysis published in the Journal of Women's Health found that fewer than 30% of commercially insured women with HSDD diagnoses who were prescribed bremelanotide actually filled the prescription within 90 days, with cost cited as the primary barrier [2].

Dr. Rachel Rubin, a urologist and sexual medicine specialist, has stated: "The biggest barrier to HSDD treatment isn't the science. It's the insurance infrastructure. We have FDA-approved therapies that work, and payers treat them as optional." That observation applies directly to the Alabama market, where formulary exclusions and high copays suppress utilization.

Compounded Bremelanotide in Alabama: Legality, Cost, and Access

Compounded bremelanotide is legal in Alabama when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Alabama follows the federal framework established by the Drug Quality and Security Act (DQSA) of 2013, which permits 503A pharmacies to compound copies of commercially available drugs when the prescriber documents a clinical difference for the individual patient (such as a different dose, concentration, or delivery form).

The cost difference is dramatic. Compounded bremelanotide from a 503A pharmacy typically runs approximately $140 per month, roughly 88% less than brand-name Vyleesi. The compounded formulation is usually supplied as a multi-dose vial with insulin syringes rather than a prefilled autoinjector. Patients draw up each dose themselves.

Several points matter for Alabama patients considering this route:

Prescription requirement. A licensed prescriber (MD, DO, NP, or PA with prescriptive authority in Alabama) must write a patient-specific prescription. The pharmacy cannot compound bremelanotide speculatively for general stock under 503A rules.

Pharmacy licensing. The compounding pharmacy must hold an Alabama Board of Pharmacy license or be located in a state with a reciprocal agreement. Many telehealth-affiliated compounding pharmacies ship to Alabama addresses.

Quality considerations. Compounded drugs are not FDA-approved and do not undergo the same batch-testing requirements as manufactured drugs. The FDA's guidance on compounding emphasizes that patients should verify their pharmacy's compliance history through their state board.

Clinical equivalence. No head-to-head trial compares compounded bremelanotide with the branded autoinjector. The active molecule is identical, but excipients, concentration, and delivery device differ. The Endocrine Society has noted broadly that compounded hormones should be used with appropriate clinical monitoring, a principle that extends to peptide compounds like bremelanotide [3].

Manufacturer Savings and Discount Programs

Palatin Technologies offers a savings card program for commercially insured patients. The card can reduce out-of-pocket costs to as low as $0 for eligible fills, depending on plan structure. Key eligibility rules:

• Patient must have commercial (private) insurance. Government-funded plans (Medicaid, Medicare, Tricare, VA) are excluded.
• The card covers up to a set dollar amount per fill, typically offsetting the specialty copay.
• Enrollment requires activation through the Vyleesi website or through the prescriber's office.

For uninsured Alabama patients, Palatin has periodically offered a patient assistance program (PAP) with income-based eligibility. Availability and terms change annually, so patients should contact Palatin directly or ask their prescriber to check current PAP status.

Independent prescription discount platforms (GoodRx, RxSaver, SingleCare) list Vyleesi coupons for Alabama pharmacies, but the discounted price still typically exceeds $900 per month for the brand product. These platforms offer more meaningful savings on generic medications; for a single-source brand like Vyleesi, the discount ceiling is low.

Telehealth Access to Vyleesi in Alabama

Alabama permits telehealth prescribing of Vyleesi. The Alabama Board of Medical Examiners and the Alabama Collaborative Practice Act both allow synchronous audio-video telehealth visits for establishing the prescriber-patient relationship required to write a prescription. No in-person visit is mandated before prescribing bremelanotide.

This matters for women in rural Alabama counties where sexual medicine specialists are scarce. A patient in Dothan or Tuscaloosa can consult a telehealth provider licensed in Alabama, receive a diagnosis of HSDD, and obtain a prescription that ships from a licensed pharmacy to her home. Several national telehealth platforms now include HSDD in their service lines.

The American College of Obstetricians and Gynecologists (ACOG) supports telehealth for sexual health concerns, noting that "telemedicine can reduce barriers to care for conditions that patients may find difficult to discuss in person" [4]. Alabama's telehealth parity law (Act 2022-354) requires insurers to cover telehealth visits at the same rate as in-person visits, meaning the consultation itself should not cost more simply because it occurs virtually.

How Vyleesi Compares to Other HSDD Options in Alabama

Vyleesi is one of two FDA-approved pharmacotherapies for HSDD in premenopausal women. The other is flibanserin (Addyi), a daily oral pill.

Cost comparison in Alabama (approximate, 2026):

• Vyleesi (brand): $1,200/month
• Addyi (brand flibanserin): $400 to $500/month
• Generic flibanserin: $30 to $80/month
• Compounded bremelanotide: $140/month

Flibanserin requires daily dosing regardless of sexual activity, carries an alcohol interaction warning (the FDA label includes a boxed warning about hypotension and syncope with alcohol), and needs 8 to 12 weeks of continuous use before efficacy assessment. Bremelanotide is taken as needed, works within hours, and does not interact with alcohol [5].

The RECONNECT trials showed that bremelanotide's most common adverse effects were nausea (40% in the treatment arm vs. 1% placebo), flushing (20%), and injection-site reactions (13%) [1]. Nausea was generally mild, occurred mainly with early doses, and diminished with repeated use. The as-needed dosing model means patients who experience side effects can simply skip a dose without the discontinuation concerns associated with daily flibanserin.

A 2021 systematic review in the Journal of Sexual Medicine concluded that both bremelanotide and flibanserin produce clinically meaningful improvements in desire, but that the effect sizes are modest and patient selection is important [6]. For Alabama women, the practical decision often comes down to cost tolerance, preference for daily versus as-needed dosing, and whether their insurer covers one option but not the other.

Step-by-Step: Getting the Lowest Price in Alabama

For an Alabama woman with a confirmed HSDD diagnosis seeking the most affordable bremelanotide access, this sequence covers the ground:

1. Check your formulary. Call the number on the back of your insurance card and ask specifically whether bremelanotide (Vyleesi) is covered, what tier it sits on, and whether prior authorization or step therapy applies.

2. Apply the manufacturer savings card. If commercially insured, activate the Palatin savings card before your first fill. The card stacks on top of insurance and can eliminate the copay entirely.

3. Request prior authorization proactively. Have your prescriber submit PA paperwork before sending the prescription to the pharmacy. Include FSFI scores, documentation of HSDD duration, and notes on any prior treatments attempted.

4. If denied, appeal. Alabama insurance regulations require a formal appeal process. Your prescriber can submit a letter of medical necessity citing the RECONNECT trial data and FDA approval.

5. Consider compounded bremelanotide. If brand-name Vyleesi remains unaffordable after insurance and savings card, ask your prescriber about a compounded formulation from a licensed 503A pharmacy. Confirm the pharmacy's Alabama license or out-of-state shipping authorization.

6. Use telehealth if needed. If your local provider is unfamiliar with HSDD treatment, a telehealth consultation with a sexual medicine specialist can provide both the diagnosis and the prescription.

The price gap between $1,200 and $140 per month is large enough that compounded bremelanotide represents the most accessible path for uninsured and underinsured Alabama patients. The clinical tradeoff is the loss of the prefilled autoinjector's convenience and the absence of FDA manufacturing oversight on the compounded product.

Alabama-Specific Regulatory Notes

Alabama does not impose state-level restrictions on bremelanotide beyond federal scheduling and prescribing requirements. The drug is not a controlled substance. No state legislative proposals affecting bremelanotide access or compounding were pending in the 2026 Alabama legislative session as of May 2026.

The Alabama Board of Pharmacy oversees compounding pharmacies operating within the state. Out-of-state 503A pharmacies shipping to Alabama patients must register with the board. Patients can verify a pharmacy's license status through the Alabama Board of Pharmacy online lookup tool.

The Alabama Department of Public Health does not maintain a separate formulary or access restriction for bremelanotide. Prescriptive authority follows standard scope-of-practice rules: physicians, nurse practitioners (with collaborative agreements where required), and physician assistants can all prescribe Vyleesi in Alabama.